---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-006581"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:32:07.894487+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics announces FDA removal of clinical hold on CP101 IND; prepares to resume PRISM4 Phase 3 trial

## Summary
- FDA lifted clinical hold on CP101 IND after Finch provided SARS-CoV-2 screening data and revised consent language.
- CP101 is an oral microbiome therapeutic for recurrent C. difficile infection, in late-stage development.
- PRISM4 enrollment to resume after manufacturing activities, quality updates, and FDA agreement on protocol amendment and validation package.
- Timing update for PRISM4 and AUSPIRE Phase 1b trial of FIN-211 expected with Q1 2022 results.

## SEC filing metadata
- accession: 0000950170-22-006581
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022006581/0000950170-22-006581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022006581/fnch-20220428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-006581
- JSON: https://secwatch.observer/filing/0000950170-22-006581.json
- Plain text: https://secwatch.observer/filing/0000950170-22-006581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.